Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:51:56.243Z.
Calculation as of: 2026-10-06T14:51:56.243Z.
Quote observation: 2026-10-06T14:50:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.95B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.00B
EBITDA Yield
3.76%
TTM Avg
3.64%
3Y Avg
2.44%
5Y Avg
2.44%
Market Cap
$2.01B
EBITDA Yield
8.99%
TTM Avg
5.82%
3Y Avg
4.86%
5Y Avg
4.86%
Market Cap
$2.02B
EBITDA Yield
N/A
TTM Avg
4.83%
3Y Avg
4.83%
5Y Avg
4.83%
Market Cap
$1.89B
EBITDA Yield
0.59%
TTM Avg
0.62%
3Y Avg
0.49%
5Y Avg
0.49%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.95B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.97B | N/A | 0.87% | 0.82% | 0.82% |
| Immunome, Inc. (IMNM)vs › | $1.93B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 3.76% | 3.64% | 2.44% | 2.44% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.00B | N/A | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 8.99% | 5.82% | 4.86% | 4.86% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 4.83% | 4.83% | 4.83% |
| Azenta, Inc. (AZTA)vs › | $1.89B | 1.95% | 4.45% | 3.20% | 2.40% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 0.59% | 0.62% | 0.49% | 0.49% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
